Prasinezumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized (from mouse) |
| Target | α-Synuclein |
| Clinical data | |
| Other names | NEOD002; NEOD-002; PRX002; PRX-002; RG7935; RG-7935; RO7046015; RO-7046015 |
| Routes of administration | Intravenous |
| Drug class | Monoclonal antibody |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
Prasinezumab (INN, USAN; developmental code names NEOD002, PRX-002, RG-7935, RO-7046015) is an anti-α-synuclein drug acting as a monoclonal antibody against α-synuclein which is under development for the treatment of Parkinson's disease. No significant effect on disease progression was seen in a 52-week phase 2 clinical trial.There have been concerns about research misconduct and data fabrication relevant to prasinezumab.
As of May 2024, prasinezumab is in phase 3 clinical trials for Parkinson's disease. It is under development by Prothena Biosciences and Roche.